10177-06-7

Basic information

• Product Name: 2,6-DICHLORO-5-PHENYLNICOTINONITRILE
• Synonyms: 2,6-DICHLORO-5-PHENYLNICOTINONITRILE
• CAS NO: 10177-06-7
• Molecular Formula: C₁₂H₆Cl₂N₂
• Molecular Weight: 249.1
• Mol File: 10177-06-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,6-DICHLORO-5-PHENYLNICOTINONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-5-PHENYLNICOTINONITRILE(10177-06-7)
• EPA Substance Registry System: 2,6-DICHLORO-5-PHENYLNICOTINONITRILE(10177-06-7)

Safety Data

• Hazardous Substances Data: 10177-06-7(Hazardous Substances Data)

Usage

General Description

2,6-dichloro-5-phenylnicotinonitrile is a chemical compound with the molecular formula C13H6Cl2N2. It is a white crystalline powder with a melting point of 160-162°C. 2,6-dichloro-5-phenylnicotinonitrile is widely used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It has been reported to exhibit insecticidal and herbicidal activity, making it valuable in the agricultural industry. Additionally, it has also been used in the preparation of heterocyclic compounds and as a building block in organic synthesis. However, it is important to handle this chemical with caution due to its potential health hazards and environmental impact.

Upstream product

• 17838-69-6 ethyl 3-oxo-2-phenylpropanoate 
• 101-97-3 Ethyl 2-phenylethanoate 
• 10177-05-6 2,6-dihydroxy-5-phenylnicotinonitrile 

Downstream Products

• 1299493-01-8 2-chloro-6-(2-(dimethylamino)ethylamino)-5-phenylnicotinonitrile 

Relevant articles and documents

Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors

Among the recently investigated targets for cancer therapy is the c-Src non-receptor tyrosine kinase. Indeed research around deregulated activity of this enzyme has proven its role in tumor progression, while the beneficial effects of c-Src inhibitors in several pathological models has also been demonstrated. We report here the preparation and pharmacological profile of a novel series of c-Src inhibitors that was elaborated around a 3-amino-thieno[2,3-b]pyridine discovered during an HTS campaign. c-Src enzyme inhibition and c-Src inhibition were investigated in a series of related compounds derived from the initial hit. Molecular modeling as well as X-ray studies on one active compound allowed us to hypothesize on ligand orientation and interactions within the ATP hydrophobic pocket. Design and synthesis of structural analogs then led to new ligands possessing quite efficient enzymatic and c-Src inhibition. The structure-activity elements disclosed in this study shed light on the role played by substituents on the thienopyridine ring as well as the impact of other aromatic moieties in the molecule when interacting with the enzyme.